Transforming growth factor β1 gene polymorphism in postmenopausal osteoporosis

Transforming growth factor β1 gene polymorphism in postmenopausal osteoporosis

Objective. Transforming growth factor β1 (TGF β1) prevails among growth factors in bone. It is produced by osteoblasts and is able to hamper osteoclast proliferation, activate and stimulate osteoblasts precursors proliferation and differentiation. At present several polymorphisms located in differen...

Full description

Saved in:

Bibliographic Details
Main Authors:	M Y Krylov, K A Maslova, T A Korotkova, N A Toroptsova, O A Nikitinskaya, N V Demin, V A Myakotkin, L I Benevolenskaya
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2009-02-01
Series:	Научно-практическая ревматология
Subjects:	osteoporosis bone mineral density snp tgf β1 gene polymorphism
Online Access:	https://rsp.mediar-press.net/rsp/article/view/472
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

ASSOCIATION OF INTERLEUKIN-1β GENE POLYMORPHISM WITH POSTMENOPAUSAL OSTEOPOROSIS IN WOMEN IN THE RUSSIAN POPULATION
by: M. Yu. Krylov, et al.
Published: (2015-10-01)

Association of transforming growth factor (TGF) p1 T(861-20)C polymorphism with bone mineral density and TGFip gene expression in postmenopausal osteoporosis
by: Elena Vasilyevna Chetina, et al.
Published: (2012-04-01)

Estrogenic receptors a and p gene polymorphisms in postmenopausal osteoporosis
by: K A Maslova, et al.
Published: (2008-06-01)

Mineral bone density association with estrogen alpha receptor gene (ESRa) polymorphisms at postmenopausal osteoporosis
by: M Y Krylov, et al.
Published: (2005-02-01)

LEPTIN A19G POLYMORPHISM AND LEPTIN RECEPTOR Gln223Arg AND Lys109Arg POLYMORPHISMSIN POSTMENOPAUSAL OSTEOPOROSIS
by: Mikhail Yur'evich Krylov, et al.
Published: (2010-10-01)

MOLECULAR GENETIC TESTING OF OSTEOPOROSIS SUSCEPTIBILITY IN POSTMENOPAUSAL WOMEN IN MOSCOW
by: V A Myakotkin, et al.
Published: (2011-04-01)

FARNESYL DIPHOSPHATE SYNTHASE (FDRS) AND GERANYLGERANYL DIPHOSPHATE SYNTHASE (GGSP1) GENE POLYMORPHISMS AND EFFICIENCY OF THERAPY WITH BISPHOSPHONATES IN RUSSIAN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS: A PILOT STUDY
by: M. Yu. Krylov, et al.
Published: (2016-03-01)

Adherence to treatment with denosumab, its efficacy and safety in women with postmenopausal osteoporosis in clinical practice
by: N. V. Toroptsova, et al.
Published: (2016-01-01)

STRONTIUM RANELATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS: IMPACT OF VITAMIN D RECEPTOR AND MONOCYTE CHEMOATTRACTANT PROTEIN-1 GENE POLYMORPHISMS ON BONE MINERAL DENSITY: A PILOT STUDY
by: M. Yu. Krylov, et al.
Published: (2017-07-01)

Search for genetic markers determining the efficiency of therapy with bisphosphonates in Russian women with postmenopausal osteoporosis: A pilot study
by: M. Yu. Krylov, et al.
Published: (2016-10-01)

Analysis of alkaline phosphatase, soluble acid phosphatase, low density lipoprotein and vitamin D binding protein gene polymorphisms as possible gene-candidates participating in mineral bone density determination in women with primary osteoporosis in postmenopause
by: M Y Krylov, et al.
Published: (2004-06-01)

Strontium ranelate in the treatment of postmenopausal osteoporosis: results of administration in clinical practice
by: N V Toroptsova, et al.
Published: (2008-06-01)

THREE YEARS' EXPERIENCE WITH THE BIOLOGICAL AGENT DENOSUMAB USED TO TREAT WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS: EFFICACY, SAFETY AND TREATMENT ADHERENCE
by: N. V. Toroptsova, et al.
Published: (2017-07-01)

Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: results of 1-year study in clinical practice
by: O. V. Dobrovolskaya, et al.
Published: (2019-05-01)

Assessment of genes LRP5, BVP4, TGF^l polymorphisms significance in postmenopausal osteoporosis
by: KA Myakotkin, et al.
Published: (2008-06-01)

THE EXPRESSION OF GENES ASSOCIATED WITH OSTEOBLAST DIFFERENTIATION AND THE MAMMALIAN TARGET OF RAPAMYCIN (mTOR) IN THE BLOOD OF PATIENTS WITH OSTEOPOROSIS
by: E. V. Chetina, et al.
Published: (2011-06-01)

Prophylaxis of primary osteoporosis in women with complex drug Calcemin Advance (results of an open year’s study)
by: O A Nikitinskaya, et al.
Published: (2008-06-01)

Efficacy and safety of ibandronat tablets for treatment of postmenopausal osteoporosis
by: N. V. Toroplsova, et al.
Published: (2005-10-01)

Is there an association between osteoporosis and uric acid?
by: N. V. Toroptsova, et al.
Published: (2024-12-01)

Association between polymorphisms of glucagon-like peptide-1 receptor gene and susceptibility to osteoporosis in Chinese postmenopausal women
by: Xiaoxue Bao, et al.
Published: (2024-12-01)

Primary osteoporosis prophylaxis with different calcium preparations
by: N. V. Toroptsova, et al.
Published: (2005-02-01)

Risk factors and bone mineral density in predicting the risk of fracture in postmenopausal women
by: O. A. Nikitinskaya, et al.
Published: (2016-09-01)

Risk factors for low bone mineral density in postmenopausal women with systemic sclerosis
by: A. O. Efremova, et al.
Published: (2021-10-01)

Treatment of osteoporosis in clinical practice: first experience with the Russian generic drug of zoledronic acid
by: N. V. Toroptsova, et al.
Published: (2022-05-01)

Investigating the role of osteoprotegerin gene polymorphic variants in osteoporosis
by: Bulat I. Yalaev, et al.
Published: (2021-03-01)

The use of bisphosphonates for the treatment and prevention of osteoporosis
by: O. A. Nikitinskaya, et al.
Published: (2022-08-01)

OSTEOPOROSIS TREATMENT ADHERENCE: RESULTS FROM A RETROSPECTIVE COHORT STUDY
by: O. A. Nikitinskaya, et al.
Published: (2019-09-01)

Zoledronic acid in the treatment of osteoporosis: indications for use
by: Nataliya Vladimirovna Toroptsova, et al.
Published: (2011-06-01)

TREATMENT ADHERENCE IN PATIENTS WITH OSTEOPOROSIS IN DAILY CLINICAL PRACTICE
by: N. V. Toroptsova, et al.
Published: (2014-06-01)

OSTEOPOROSIS: ASSESSMENT OF A RISK FOR RECURRENT LOW-TRAUMA FRACTURES IN POSTMENOPAUSAL WOMEN
by: O. V. Dobrovolskaya, et al.
Published: (2016-03-01)

Osteoporosis and sarcopenia in women with rheumatoid arthritis
by: O. V. Dobrovolskaya, et al.
Published: (2020-05-01)

Evaluation of relationship between SPON1 gene and genetic susceptibility of postmenopausal osteoporosis
by: Wenlong Ma, et al.
Published: (2020-01-01)

Denosumab is the first gene engineered agent for the treatment of osteoporosis
by: O A Nikitinskaya, et al.
Published: (2012-09-01)

Unraveling the causal role of TGF-βRII in osteoporosis and the potential of its associated differential genes as novel targets
by: Xinyu Zhu, et al.
Published: (2025-08-01)

Osteoporosis and its complications: treatment adherence and possibilities of its enhancement
by: O V Dobrovol'skaya, et al.
Published: (2011-09-01)

STRONTIUM RANELATE IS THE DRUG OF CHOICE IN THE TREATMENT OF OSTEOPOROSIS
by: Nataliya Vladimirovna Toroptsova
Published: (2010-09-01)

THE PLACE OF STRONTIUM RANELATE IN THE TREATMENT OF PATIENTS WITH OSTEOPOROSIS (RESULTS OF THE MARC PROGRAM)
by: O. A. Nikitinskaya, et al.
Published: (2018-09-01)

SYSTEMIC OSTEOPOROSIS AND PSORIATIC ARTHRITIS: CURRENT UNDERSTANDING OF THE PROBLEM
by: O. V. Dobrovolskaya, et al.
Published: (2017-10-01)

The Effect of Alendronate Treatment on Bone Density and Bone Markers in Postmenopausal Osteoporosis
by: S. Akı, et al.
Published: (2002-03-01)

Associations of polymorphisms in the gene promoters of cytokines and matrix metalloproteinases with bone mineral density in postmenopausal type 2 diabetic women
by: Olga N. Fazullina, et al.
Published: (2018-03-01)